MANAGEMENT OF RAISED BLOOD-PRESSURE IN NEW-ZEALAND - A DISCUSSION DOCUMENT

被引:227
作者
JACKSON, R
BARHAM, P
BILLS, J
BIRCH, T
MCLENNAN, L
MACMAHON, S
MALING, T
机构
[1] UNIV AUCKLAND,DEPT GEN PRACTICE,GOODFELLOW UNIT,AUCKLAND,NEW ZEALAND
[2] ROTHERHAM MED CTR,CANTERBURY,NEW ZEALAND
[3] HOKIANGA HLTH SERV,RAWENE,NEW ZEALAND
[4] WAITANGIRUA HLTH CTR,WELLINGTON,NEW ZEALAND
[5] UNIV AUCKLAND,DEPT MED,CLIN TRIALS RES UNIT,AUCKLAND,NEW ZEALAND
[6] UNIV OTAGO,WELLINGTON SCH MED,DEPT MED,DUNEDIN,NEW ZEALAND
关键词
D O I
10.1136/bmj.307.6896.107
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A report to the National Advisory Committee on Core Health and Disability Support Services, New Zealand, on the management of raised blood pressure recommends that decisions to treat raised blood pressure should be based primarily on the estimated absolute risk of cardiovascular disease rather than on blood pressure alone. In general, patients with a blood pressure of 150-170 mm Hg systolic or 90-100 mm Hg diastolic, or both, should be given treatment to lower blood pressure if the risk of a major cardiovascular disease event in 10 years is more than about 20%. The results of clinical trials indicate that, at this level of absolute risk, 150 people would require treatment to reduce the annual number of cardiovascular events by about one. Implementation of these recommendations may result in a smaller proportion of people aged under 60, particularly women, receiving treatment but an increased proportion of older people treated. In the absence of specific contraindications, low dose diuretics and low dose beta blockers should be considered for first line treatment, since for only these drug groups is there direct evidence of reduced risk of stroke and coronary disease in people with raised blood pressure.
引用
收藏
页码:107 / 110
页数:4
相关论文
共 12 条
  • [1] AN UPDATED CORONARY RISK PROFILE - A STATEMENT FOR HEALTH-PROFESSIONALS
    ANDERSON, KM
    WILSON, PWF
    ODELL, PM
    KANNEL, WB
    [J]. CIRCULATION, 1991, 83 (01) : 356 - 362
  • [2] RELATION BETWEEN DOSE OF BENDROFLUAZIDE, ANTIHYPERTENSIVE EFFECT, AND ADVERSE BIOCHEMICAL EFFECTS
    CARLSEN, JE
    KOBER, L
    TORPPEDERSEN, C
    JOHANSEN, P
    [J]. BRITISH MEDICAL JOURNAL, 1990, 300 (6730) : 975 - 978
  • [3] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT
    COLLINS, R
    PETO, R
    MACMAHON, S
    HEBERT, P
    FIEBACH, NH
    EBERLEIN, KA
    GODWIN, J
    QIZILBASH, N
    TAYLOR, JO
    HENNEKENS, CH
    [J]. LANCET, 1990, 335 (8693) : 827 - 838
  • [4] CRUICKSHANK JM, 1987, LANCET, V1, P581
  • [5] THE EVOLUTION OF ANTIHYPERTENSIVE THERAPY
    KAWACHI, I
    WILSON, N
    [J]. SOCIAL SCIENCE & MEDICINE, 1990, 31 (11) : 1239 - 1243
  • [6] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .1. PROLONGED DIFFERENCES IN BLOOD-PRESSURE - PROSPECTIVE OBSERVATIONAL STUDIES CORRECTED FOR THE REGRESSION DILUTION BIAS
    MACMAHON, S
    PETO, R
    CUTLER, J
    COLLINS, R
    SORLIE, P
    NEATON, J
    ABBOTT, R
    GODWIN, J
    DYER, A
    STAMLER, J
    [J]. LANCET, 1990, 335 (8692) : 765 - 774
  • [7] EFFECT OF CAPTOPRIL ON MORTALITY AND MORBIDITY IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL-INFARCTION - RESULTS OF THE SURVIVAL AND VENTRICULAR ENLARGEMENT TRIAL
    PFEFFER, MA
    BRAUNWALD, E
    MOYE, LA
    BASTA, L
    BROWN, EJ
    CUDDY, TE
    DAVIS, BR
    GELTMAN, EM
    GOLDMAN, S
    FLAKER, GC
    KLEIN, M
    LAMAS, GA
    PACKER, M
    ROULEAU, J
    ROULEAU, JL
    RUTHERFORD, J
    WERTHEIMER, JH
    HAWKINS, CM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (10) : 669 - 677
  • [8] RUSSEL D, 1991, LIFE NZ SURVEY COMMI
  • [9] 1988, EUR HEART J, V9, P8
  • [10] 1989, BMJ, V298, P694